A cost‐utility analysis of single maintenance and reliever (SMART) therapy as compared to step 3 fixed‐dose therapy in patients aged 12 years or more with uncontrolled asthma

Documenti analoghi

• Validation of the Spanish version of the Pediatric Asthma Severity Score (PASS) in a population of Hispanic children
  di: Camila Alejandra Chaparro‐Reyes, et al.
  Pubblicazione: (2024)
• Once or consecutive administration of inhaled salbutamol in children with acute asthma exacerbation: Is an additional dose beneficial?
  di: Ali Özdemir, et al.
  Pubblicazione: (2024)
• Get SMART? Understanding Pediatric Pulmonologists' Perspectives on Implementation of SMART
  di: Charles Slocum, et al.
  Pubblicazione: (2026)
• Severe mental health changes in patients with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy
  di: Cameron J. McKinzie, et al.
  Pubblicazione: (2024)
• Allergen immunotherapy in patients with severe asthma: A need for prospective trials
  di: Margaret P. Huntwork, et al.
  Pubblicazione: (2024)